Your fact-checks will appear here
The approval of Donanemab (Kisunla) for Alzheimer's treatment and its full approval.
Dr. Sanjay Gupta does not claim to have discovered a cure for Alzheimer’s; his public reporting and books emphasize prevention, lifestyle changes, and coverage of emerging therapies rather than a sing...
Two categories of reliable, FDA‑approved treatments exist for Alzheimer’s disease today: longstanding symptomatic therapies that can modestly improve cognition or behavior, and a new class of anti‑amy...
FDA approval of a dementia treatment rests on a sequence of regulatory steps: preclinical research, phased clinical trials demonstrating safety and efficacy, review under standard or expedited pathway...
Dr. Sanjay Gupta reports neither a proven cure for Alzheimer’s disease nor does he claim to have personally discovered one; his recent reporting highlights new treatments that slow progression and emp...
The evaluates drugs through either traditional (full) approval or the Accelerated Approval pathway; the latter allows earlier market access when a drug affects a surrogate endpoint “reasonably likely ...
Three monoclonal antibody treatments that target amyloid-beta have been approved by U.S. regulators in recent years: aducanumab (Aduhelm) in 2021, lecanemab (Leqembi) in 2023 with updated maintenance ...
As of 2025 the FDA’s approved arsenal for Alzheimer’s disease includes new anti-amyloid monoclonal antibodies for early-stage illness, longstanding symptom‑relief drugs, and a few recent approvals for...
The FDA now recognizes two classes of treatments for Alzheimer’s: disease‑modifying, amyloid‑targeting monoclonal antibodies that can modestly slow clinical decline in early disease, and older symptom...